U.S. Missionary Gets Experimental Ebola Treatment in Germany

When Dr. Peter Stafford contracted Ebola while serving as a missionary in the Democratic Republic of Congo, medical teams immediately began exploring every possible treatment option. Now receiving care in a German hospital, he's being given experimental therapies designed to reduce symptoms and help his body fight the virus.

The case highlights both the challenges and determination facing health workers during the current outbreak. Nearly 750 people have been infected with the rare Bundibugyo strain of Ebola in the Congo, and 177 have died.

What makes Dr. Stafford's treatment particularly noteworthy is that no vaccines or drugs are specifically approved for this Ebola strain. Yet doctors aren't giving up. They're using experimental medications that show promise based on research and previous outbreak responses.

U.S. Centers for Disease Control and Prevention officials confirmed Friday that multiple therapies are being administered. While privacy laws prevent them from sharing specific treatment details, the Serge Christian mission organization has identified the patient and is supporting his care.

Why This Inspires

Dr. Stafford's story reminds us why medical missionaries risk so much to serve communities facing deadly diseases. These healthcare workers don't just treat illness. They bring hope to places where medical resources are scarce and outbreaks can devastate entire regions.

The willingness of medical teams to try experimental treatments also shows how far science has come. Even without approved drugs for this specific strain, researchers have developed promising therapies that offer fighting chances where none existed before.

Germany's decision to accept and treat Dr. Stafford demonstrates the global medical community's commitment to saving every life possible. International cooperation in healthcare means no one fights alone, whether they're a missionary doctor or a family in the Congo.

The story also shines light on the broader response to this outbreak. While 177 deaths represent tremendous loss, the fact that medical teams have identified cases, tracked the spread, and begun treatment for hundreds shows a coordinated effort that previous generations never had.

Every experimental treatment tried today builds knowledge for tomorrow. The therapies Dr. Stafford receives could help inform better treatments for future patients, turning one person's fight into hope for many.

His colleagues at Serge Christian continue their mission work, knowing that trained medical professionals willing to serve in difficult places make the difference between outbreaks contained and outbreaks that spiral.

Medical science keeps pushing forward, one patient and one experimental treatment at a time.